Temozolomide in the management of dopamine agonist-resistant prolactinomas.
about
Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas with Adjuvant Temozolomide Chemotherapy: A ReviewThe pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomasTemozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina.Expression profiling of O(6) methylguanine-DNA-methyl transferase in prolactinomas: a correlative study of promoter methylation and pathological features in 136 cases.Temozolomide: Anti-tumor effect on giant, invasive and resistant pediatric prolactinoma.A Rapid Biochemical and Radiological Response to the Concomitant Therapy with Temozolomide and Radiotherapy in an Aggressive ACTH Pituitary Adenoma.Giant prolactinomas: the therapeutic approach.Current treatment options for hyperprolactinemia.Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.Management of medically refractory prolactinoma.Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.The safety of treatments for prolactinomas.How effective is temozolomide for treating pituitary tumours and when should it be used?Temozolomide treatment of pituitary carcinomas and atypical adenomas: systematic review of case reportsRecent Progress in the Medical Therapy of Pituitary TumorsTreatment-resistant pediatric giant prolactinoma and multiple endocrine neoplasia type 1.Ten-year follow-up of a giant prolactinoma.ACTH-secreting Crooke cell carcinoma of the pituitary.Pituitary Carcinoma in a Patient with an SDHB Mutation.Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date.MGMT assessment in pituitary adenomas: comparison of different immunohistochemistry fixation chemicals.Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.Macroprolactinoma causing VI, X, XII cranial nerve palsies nearly 30 years after initial treatment.Effective long-term temozolomide rechallenge in a macroprolactinoma
P2860
Q26739267-FE4A37F8-D9F3-44E8-BCFB-83CB8A65809BQ26772167-0340CDBF-60DB-40C0-A316-48783B9BBDCAQ35708559-A4EBFFA8-98C7-4D24-A31C-1ACF21FC891DQ35785924-F090DB94-FE77-4EC4-8FFB-B108E375A95BQ37413985-142F4205-16D0-4C18-B56E-719270E4444FQ37710210-47A28596-E669-46C3-AD0A-9982989C534BQ38105620-71ABB4D1-EB38-4F02-B095-AE7A5670994FQ38112205-46A043E2-9917-4CD2-B8B9-12832AE0F0F2Q38129776-19F53AAD-0937-4D64-8D8B-579DD02D4C99Q38154516-2930339D-5310-4FFE-9068-A967170D1A65Q38650974-C6D04811-8586-462D-8478-0ADC7688D32DQ38726058-CB5F3B31-C518-4233-859E-DE704722D573Q38825694-F50106FD-B2B9-444D-BA33-7876B65E7047Q38934576-250E98C5-3886-4270-A498-DE4C03193F4AQ39420116-AC088508-EEEF-4E05-B62A-DF2D3821E05DQ40730569-449918D7-0173-4561-870A-F4E89FB72D26Q44183655-50186E1C-A740-44B1-95DA-19DD64565D69Q44886396-EF332360-9C46-4D19-88C4-3BE97CAA5688Q45805389-398B82FA-9D6D-4FBD-9B43-258D5CAFB2D1Q47115174-C5D8B0D9-EA12-4862-A5CB-C95DDA20E7F3Q49979233-3B5CEC73-D6C6-4EF3-9893-D5F738822CC7Q53629828-C88A8682-223B-40A9-9395-FEAD136A044CQ55553651-1C03C540-2A90-4D75-8E46-2FC6B9986A37Q57299913-BE42E1AA-D7F8-43DE-AFB8-D96D3AC3BCD2
P2860
Temozolomide in the management of dopamine agonist-resistant prolactinomas.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Temozolomide in the management of dopamine agonist-resistant prolactinomas.
@en
Temozolomide in the management of dopamine agonist-resistant prolactinomas.
@nl
type
label
Temozolomide in the management of dopamine agonist-resistant prolactinomas.
@en
Temozolomide in the management of dopamine agonist-resistant prolactinomas.
@nl
prefLabel
Temozolomide in the management of dopamine agonist-resistant prolactinomas.
@en
Temozolomide in the management of dopamine agonist-resistant prolactinomas.
@nl
P2093
P2860
P1476
Temozolomide in the management of dopamine agonist-resistant prolactinomas
@en
P2093
C R Buchanan
D Dworakowska
D Lipscomb
J A Gilbert
N W Thomas
P Riordan-Eva
S J B Aylwin
P2860
P304
P356
10.1111/J.1365-2265.2012.04373.X
P577
2012-06-01T00:00:00Z